Sylvie Mader, Ph.D.

Awards & Honours

  • CIBC Research Chair in Breast Cancer of the Université de Montréal, 2002–
  • National Scholar, Fonds de la recherche en santé du Québec, 2003-
  • Senior Scholar, Fonds de la recherche en santé du Québec, 2003-2007
  • Junior II Scholar, Fonds de la recherche en santé du Québec, 1999-2003
  • Junior I Scholar, Fonds de la recherche en santé du Québec, 1995-1999
  • Postdoctoral Award, Medical Research Council of Canada, 1994-1995
  • Postdoctoral Award, Human Frontier Science Program Organization, 1992-1994


  • Postdoctoral training with Professor Nahum Sonenberg, McGill University, 1992-1995
  • Ph.D. in Bbiochemistry with Professor Pierre Chambon, Université Louis Pasteur (Strasbourg I) 1991
  • DEA in Microbiology, Université PARIS VI-Institut Pasteur, 1987
  • Masters in Biochemistry, Université PARIS VI, 1986
  • ‘Licence’ in Biochemistry, Université PARIS VI, 1985
  • École Normale Supérieure, Paris, 1984-1988

Research Support

  • Canadian Institutes of Health Research
  • Canadian Cancer Society Research Institute
  • Canadian Breast Cancer Research Alliance
  • Canadian Cancer Society
  • Quebec Breast Cancer Foundation
  • Fonds québécois de la recherche sur la nature et les technologies

After training in France at Ecole Normale Supérieure de Paris, Université Paris VI and Institut Pasteur, Sylvie Mader joined the team of Professor Pierre Chambon in Strasbourg for a Ph.D. in Biochemistry at the Laboratoire de Génétique Moléculaire des Eucaryotes, during which she characterized the mechanisms of target gene regulation by nuclear receptors. She then trained as a postdoctoral fellow with Professor Nahum Sonenberg at the Biochemistry department at McGill University, where she uncovered a mechanism of translational control involving formation of competitive complexes with the translation intiation factor eIF4E. Sylvie Mader put together her research team at Université de Montréal in 1995, with a focus on the therapeutic modulation of molecular signaling pathways involved in breast cancer. Since 2002, she holds the CIBC Breast Cancer Research Chair at Université de Montréal.

Since joining IRIC in 2005, Sylvie Mader and her team use cutting-edge technologies such as functional genomics, proteomics, bioinformatics and biophysics to identify novel therapeutic targets and design new drugs for breast cancer treatment. In particular, her team is studying nuclear receptor signaling pathways, which are attractive targets for drug development. She is also analyzing the mechanisms of mammary cell differentiation and tumorigenesis in cultured cells and animal models.

Follow IRIC

Logo UdeM